[Effectiveness of the new Soviet immunomodulator mielopid in the combined treatment of patients with chronic pyoderma].
Thirty-four patients with chronic pyoderma have been examined. Fifteen of these have been treated with mielopid (18 mg per course). Immunologic and clinical examinations carried out in 3-10 months after therapy have demonstrated a wide-spectrum immunostimulating action of the new drug.
Petrova
I V
IV
Leshchenko
G M
GM
Bystritskaia
T F
TF
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011711:Pyoderma / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence
D000276:Adjuvants, Immunologic; D010455:Peptides
Effektivnost' novogo otechestvennogo immunomoduliatora mielopida pri kompleksnom lechenii bol'nykh khronicheskoĭ piodermieĭ.